As the field of cancer immunotherapy continues to evolve, clinicians need to be informed about the most up-to-date strategies for managing immunotherapy-related toxicities. Providing continuing education on early recognition and effective management of immunotherapy-related toxicities is crucial to ensure optimal outcomes for an increasing number of patients treated with immunotherapy.

The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Continuing education is, therefore, essential for clinicians to stay informed about the efficacy and safety data for these systemic therapy options.

With expanding treatment options, clinicians should understand important criteria used in selecting optimal first-and subsequent-line therapies for individuals with metastatic breast cancer. For clinicians, staying up to date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.

As a result of the therapeutic advances and clinical research affecting the management of patients with breast cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.